<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138719</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-KAL-BC-11</org_study_id>
    <nct_id>NCT04138719</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer</brief_title>
  <official_title>Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The fifth medical center of PLA general hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open, randomized, comparison study. Triple-negative breast cancer
      (TNBC) is a term applied to breast cancer cases that have &lt;1% expression of the estrogen
      receptor (ER) and the progesterone receptor (PR) and do not over express HER2.

      Neoadjuvant therapy is often used to reduce the size of tumors, especially in locally
      advanced tumors. The purpose of this therapy is to make part of patients operable and to
      facilitate breast-conserving surgery.

      The purpose of this study is to assess the efficacy and safety of the following two
      proposals: nab-paclitaxel plus carboplatin versus nab-paclitaxel plus epirubicin, in order to
      provide support for rational clinical application.

      The total number of patients to be included in this study is 520 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2019</start_date>
  <completion_date type="Anticipated">June 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR (pathological complete response)</measure>
    <time_frame>3 years</time_frame>
    <description>No residual infiltrating cancer cells were found in surgical specimens of breast and axillary lymph nodes; residual cancer cells in situ in surgical specimens can also be considered to achieve pCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival（DFS）</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Triple-negative Breast Cancer</condition>
  <condition>Nab-paclitaxel</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nab-paclitaxel + Epirubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and epirubicin given IV at 75 mg/m^2 on days 1 every 21 days x 6 cycles；</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel + Carboplatin</intervention_name>
    <description>nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;</description>
    <arm_group_label>Nab-paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel + Epirubicin</intervention_name>
    <description>nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and epirubicin given IV at 75 mg/m^2 on days 1 every 21 days x 6 cycles；</description>
    <arm_group_label>Nab-paclitaxel + Epirubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with age between 18 to 70 years old;

          2. Histologically confirmed primary invasive breast cancer;

          3. Histologically confirmed triple negative breast cancer;

          4. Patients who planned to accept preoperative neoadjuvant therapy and had a mass larger
             than 2 cm.

          5. Blood specimens and 5 sections of tumor tissue at baseline, blood specimens at surgery
             can be obtained.

          6. Have at least one measurable lesion as per the RECIST criteria (version 1.1);

          7. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
             one;

          8. LVEF≥55%；

          9. Bone marrow function：neutrophils (≥1.5×10^9/L), platelets (≥100×10^9/L), hemoglobin
             (≥90 g/L);

         10. Renal and hepatic function: Serum creatinine≤ 1.5×institutional upper limit of normal
             (ULN); AST and ALT ≤ 2.5 × ULN; Total bilirubin≤1.5×ULN, or patients with Gilbert's
             syndrome ≤ 2.5 × ULN;

         11. Patients had good compliance with the planned treatment, understood the research
             process and written informed consent.

        Exclusion Criteria:

          1. Previous treatment with any cytotoxic chemotherapy, endocrine therapy, biotherapy or
             radiotherapy;

          2. Patients with heart disease above grade II (including grade II) identified by New York
             Heart Association (NYHA) scores;

          3. Patients with severe systemic infection or other serious diseases;

          4. Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants;

          5. Patients with other malignant tumors in the past five years, except for cured cervical
             carcinoma in situ and non-melanoma skin cancer;

          6. Pregnancy or lactation, as well as reproductive age patients who refused to take
             appropriate contraceptive measures in the trial;

          7. Participation in any trial drug treatment or another interventional clinical trial 30
             days before first dose was given;

          8. The researchers considered the patients who were not suitable for enrollment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zefei Jiang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The fifth medical center of PLA general hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cuizhi Geng, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Fourth Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cuizhi Geng, M.D.</last_name>
    <phone>0311-6669 6310</phone>
    <email>gengcuizhi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cuizhi Geng, M.D.</last_name>
      <phone>0311-6669 6310</phone>
      <email>gengcuizhi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Cuizhi GENG</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Triple-negative Breast Cancer</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Epirubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

